Please login to the form below

Not currently logged in
Email:
Password:

Dicerna

This page shows the latest Dicerna news and features for those working in and with pharma, biotech and healthcare.

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal. Bolsters pipeline ahead of Soliris patent protection loss. ... Alexion has signed a deal with RNAi specialists Dicerna to discover therapies for complement-mediated diseases.

Latest news

  • Boehringer adds to pipeline again with €628m Autifony CNS deal Boehringer adds to pipeline again with €628m Autifony CNS deal

    This is the second licensing deal for Boehringer in the last few weeks, coming after it added a non-alcoholic steatohepatitis (NASH) candidate from Dicerna in a $201m deal.

  • Boehringer bolsters NASH pipeline with $201m Dicerna deal Boehringer bolsters NASH pipeline with $201m Dicerna deal

    Boehringer bolsters NASH pipeline with $201m Dicerna deal. Will investigate a “new therapeutic approach”to target liver functionality. ... Boehringer Ingelheim has added another drug candidate to its pipeline for non-alcoholic steatohepatitis (NASH)

  • 15 years since the first paper published on RNA interference 15 years since the first paper published on RNA interference

    Alnylam is also involved in collaborations with companies including Genzyme, the Medicines Company and Takeda, while other biotechs, such as Dicerna, RXi and Tekmira, all have their own programmes, demonstrating a

  • RNA interference rebirth RNA interference rebirth

    founder of RNAi company Dicerna. ... Most companies active in the RNAi field, such as Alnylam, Dicerna, RXi and big pharma players like Novartis and Merck, have elected to develop double-stranded, small interfering RNA (siRNA) oligonucleotides

  • Advancing acquisitions

    In particular, the deal between Dicerna and Kyowa Hakko, if extended from the currently agreed targets, could reach a value of $1.4bn. ... Another interesting feature of this deal is that Dicerna has secured an option to co-promotion rights.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    Investment. Dicerna (biotech). 70. M&A without debt. Private equity companies are in the minority compared to acquisitions made by pharmaceutical companies for strategic reasons such as new markets or technologies.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics